一种佐剂为免疫刺激复合物（ISCOM）或黏膜淋巴组织趋化因子（mLT）的人诺如病毒样颗粒疫苗，在悉生猪疾病模型中可诱导细胞因子和抗体反应，并对同源GII.4型人诺如病毒产生保护作用。
A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model.
作者信息
Souza Menira, Costantini Veronica, Azevedo Marli S P, Saif Linda J
机构信息
Food Animal Health Research Program, Ohio Agricultural Research and Development Center (OARDC), Department of Veterinary Preventive Medicine, The Ohio State University, 1680 Madison Avenue, Wooster, OH 44691, United States.
出版信息
Vaccine. 2007 Dec 5;25(50):8448-59. doi: 10.1016/j.vaccine.2007.09.040. Epub 2007 Oct 5.
Abstract
We inoculated gnotobiotic pigs orally/intranasally with human norovirus GII.4 HS66 strain virus-like particles (VLP) and immunostimulating complexes (ISCOM) or mutant E. coli LT toxin (mLT, R192G) as mucosal adjuvants, then assessed intestinal and systemic antibody and cytokine responses and homologous protection. Both vaccines induced high rates of seroconversion (100%) and coproconversion (75-100%). The VLP+mLT vaccine induced Th1/Th2 serum cytokines and cytokine secreting cells, whereas the VLP+ISCOM vaccine induced Th2 biased responses with significantly elevated IgM, IgA and IgG antibody-secreting cells in intestine. Nevertheless, both vaccines induced increased protection rates against viral shedding and diarrhea (75-100%) compared to controls; however, only 57% of controls shed virus.
摘要
我们经口/鼻内给无菌猪接种人诺如病毒GII.4 HS66株病毒样颗粒（VLP）以及作为黏膜佐剂的免疫刺激复合物（ISCOM）或突变型大肠杆菌LT毒素（mLT，R192G），然后评估肠道和全身抗体及细胞因子反应以及同源保护作用。两种疫苗均诱导了高血清转化率（100%）和粪便转化率（75 - 100%）。VLP + mLT疫苗诱导了Th1/Th2血清细胞因子和细胞因子分泌细胞，而VLP + ISCOM疫苗诱导了偏向Th2的反应，肠道中IgM、IgA和IgG抗体分泌细胞显著升高。然而，与对照组相比，两种疫苗均诱导了针对病毒排泄和腹泻的保护率增加（75 - 100%）；不过，只有57%的对照组排出病毒。
相似文献
1
A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model.
Vaccine. 2007 Dec 5;25(50):8448-59. doi: 10.1016/j.vaccine.2007.09.040. Epub 2007 Oct 5.
2
Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.
J Virol. 2014 Sep 1;88(17):9728-43. doi: 10.1128/JVI.01249-14. Epub 2014 Jun 11.
3
Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs.
J Virol. 2000 Oct;74(19):8843-53. doi: 10.1128/jvi.74.19.8843-8853.2000.
4
Immune responses to bovine norovirus-like particles with various adjuvants and analysis of protection in gnotobiotic calves.
Vaccine. 2006 Jan 16;24(3):317-26. doi: 10.1016/j.vaccine.2005.07.071. Epub 2005 Aug 10.
5
Protective immunity and antibody-secreting cell responses elicited by combined oral attenuated Wa human rotavirus and intranasal Wa 2/6-VLPs with mutant Escherichia coli heat-labile toxin in gnotobiotic pigs.
J Virol. 2001 Oct;75(19):9229-38. doi: 10.1128/JVI.75.19.9229-9238.2001.
6
Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.
Clin Exp Immunol. 2004 Mar;135(3):361-72. doi: 10.1111/j.1365-2249.2004.02395.x.
7
Cytokine and antibody responses in gnotobiotic pigs after infection with human norovirus genogroup II.4 (HS66 strain).
J Virol. 2007 Sep;81(17):9183-92. doi: 10.1128/JVI.00558-07. Epub 2007 Jun 20.
8
Pathogenesis and immune responses in gnotobiotic calves after infection with the genogroup II.4-HS66 strain of human norovirus.
J Virol. 2008 Feb;82(4):1777-86. doi: 10.1128/JVI.01347-07. Epub 2007 Nov 28.
9
Recombinant virus-like particles of a norovirus (genogroup II strain) administered intranasally and orally with mucosal adjuvants LT and LT(R192G) in BALB/c mice induce specific humoral and cellular Th1/Th2-like immune responses.
Vaccine. 2004 Mar 12;22(9-10):1079-86. doi: 10.1016/j.vaccine.2003.10.004.
10
High titers of circulating maternal antibodies suppress effector and memory B-cell responses induced by an attenuated rotavirus priming and rotavirus-like particle-immunostimulating complex boosting vaccine regimen.
Clin Vaccine Immunol. 2006 Apr;13(4):475-85. doi: 10.1128/CVI.13.4.475-485.2006.
引用本文的文献
1
Virus Shedding and Diarrhea: A Review of Human Norovirus Genogroup II Infection in Gnotobiotic Pigs.
Viruses. 2024 Sep 7;16(9):1432. doi: 10.3390/v16091432.
2
Current trends and new approaches for human norovirus replication in cell culture: a literature review.
Arch Virol. 2024 Mar 8;169(3):71. doi: 10.1007/s00705-024-05999-4.
3
Advances in Human Norovirus Vaccine Research.
Vaccines (Basel). 2021 Jul 2;9(7):732. doi: 10.3390/vaccines9070732.
4
Evaluation of the 50% Infectious Dose of Human Norovirus Cin-2 in Gnotobiotic Pigs: A Comparison of Classical and Contemporary Methods for Endpoint Estimation.
Viruses. 2020 Aug 28;12(9):955. doi: 10.3390/v12090955.
5
Virus-like particle-based vaccines for animal viral infections.
Inmunologia. 2013 Jul-Sep;32(3):102-116. doi: 10.1016/j.inmuno.2012.08.002. Epub 2012 Oct 26.
6
Immunogenicity and Efficacy Evaluation of Subunit Astrovirus Vaccines.
Vaccines (Basel). 2019 Aug 2;7(3):79. doi: 10.3390/vaccines7030079.
7
A Lactic Acid Bacteria (LAB)-Based Vaccine Candidate for Human Norovirus.
Viruses. 2019 Mar 2;11(3):213. doi: 10.3390/v11030213.
8
Human Norovirus: Experimental Models of Infection.
Viruses. 2019 Feb 12;11(2):151. doi: 10.3390/v11020151.
9
Norovirus vaccines: Correlates of protection, challenges and limitations.
Hum Vaccin Immunother. 2016 Jul 2;12(7):1653-69. doi: 10.1080/21645515.2015.1125054. Epub 2016 Feb 2.
10
Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectives.
Future Virol. 2015;10(7):899-913. doi: 10.2217/fvl.15.57.
本文引用的文献
1
Cytokine and antibody responses in gnotobiotic pigs after infection with human norovirus genogroup II.4 (HS66 strain).
J Virol. 2007 Sep;81(17):9183-92. doi: 10.1128/JVI.00558-07. Epub 2007 Jun 20.
2
A waterborne outbreak of gastroenteritis with multiple etiologies among resort island visitors and residents: Ohio, 2004.
Clin Infect Dis. 2007 Feb 15;44(4):506-12. doi: 10.1086/511043. Epub 2007 Jan 8.
3
Binding patterns of human norovirus-like particles to buccal and intestinal tissues of gnotobiotic pigs in relation to A/H histo-blood group antigen expression.
J Virol. 2007 Apr;81(7):3535-44. doi: 10.1128/JVI.01306-06. Epub 2007 Jan 10.
4
Pathogenesis of a genogroup II human norovirus in gnotobiotic pigs.
J Virol. 2006 Nov;80(21):10372-81. doi: 10.1128/JVI.00809-06.
5
Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains.
Vaccine. 2006 Jun 12;24(24):5220-34. doi: 10.1016/j.vaccine.2006.03.080. Epub 2006 Apr 18.
6
Cytokine responses in gnotobiotic pigs after infection with virulent or attenuated human rotavirus.
J Virol. 2006 Jan;80(1):372-82. doi: 10.1128/JVI.80.1.372-382.2006.
7
Development of a new microwell hybridization assay and an internal control RNA for the detection of porcine noroviruses and sapoviruses by reverse transcription-PCR.
J Virol Methods. 2006 Mar;132(1-2):135-45. doi: 10.1016/j.jviromet.2005.10.003. Epub 2005 Nov 7.
8
Immune responses to bovine norovirus-like particles with various adjuvants and analysis of protection in gnotobiotic calves.
Vaccine. 2006 Jan 16;24(3):317-26. doi: 10.1016/j.vaccine.2005.07.071. Epub 2005 Aug 10.
9
Cellular and humoral immunity following Snow Mountain virus challenge.
J Virol. 2005 Mar;79(5):2900-9. doi: 10.1128/JVI.79.5.2900-2909.2005.
10
Norovirus transmission on cruise ship.
Emerg Infect Dis. 2005 Jan;11(1):154-8. doi: 10.3201/eid1101.040434.
Zotero 插件